Do you want to remove all your recent searches?

All recent searches will be deleted

Watch fullscreen

Non-Small Cell Lung Cancer Market 2022

Edoardo Lombarda
5 years ago|13 views
Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-non-small-cell-lung-cancer-global-drug-forecast-and-market-analysis-to-2022-market-report.html .

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets. However, while the US and Japanese markets will continue to grow, increasing cost pressures from European regulatory agencies will counteract these drivers in the EU markets.

Browse more videos